Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
about
Approved Antiviral Drugs over the Past 50 YearsIn vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diestersInhibition of human immunodeficiency virus type 1 replication in acutely and chronically infected cells by EM2487, a novel substance produced by a Streptomyces speciesSJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-24'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitroInhibition of human immunodeficiency virus replication by RD6-Y664, a novel benzylhydroxylamine derivativePyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1Characterization of human immunodeficiency virus type 1 strains resistant to the non-nucleoside reverse transcriptase inhibitor RD4-2217Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-Y1 N,N-dialkylcarbamate derivativesNP-06: a novel anti-human immunodeficiency virus polypeptide produced by a Streptomyces speciesMechanism of selective inhibition of human immunodeficiency virus by ingenol triacetateSearch for non-nucleoside inhibitors of HIV-1 reverse transcriptase using chemical similarity, molecular docking, and MM-GB/SA scoringSafety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1.Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.Antiviral therapy for human immunodeficiency virus infectionsIn search of a selective antiviral chemotherapy.Antiviral interactions of combinations of highly potent 2,4(1H,3H)-pyrimidinedione congeners and other anti-HIV agents.Clinical utility of current NNRTIs and perspectives of new agents in this class under development.The discovery of antiviral agents: ten different compounds, ten different stories.Curious discoveries in antiviral drug development: the role of serendipity.Synthesis and anti-HIV-1 activity of 1-substiuted 6-(3-cyanobenzoyl) and [(3-cyanophenyl)fluoromethyl]-5-ethyl-uracils.The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors.Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): retroviruses and hepadnaviruses.Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.Structure-activity relationship studies on new DABOS: effect of substitutions at pyrimidine C-5 and C-6 positions on anti-HIV-1 activity.3-(5-Dimethylamino-1-naphthalenesulphonyl)-2-(3-pyridyl)thiazolidine (YHI-1) selectively inhibits human immunodeficiency virus type 1.Sho-saiko-to, a traditional Kampo medicine, enhances the anti-HIV-1 activity of lamivudine (3TC) in vitro.Thiadiazole derivatives: highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro.Synthesis and anti-HIV-1 activity of new fluoro-HEPT analogues: an investigation on fluoro versus hydroxy substituents.Structure-activity relationship studies on potential non-nucleoside DABO-like inhibitors of HIV-1 reverse transcriptase.The synthesis of novel 6,5- and 6,6-membered fused heterocyclic compounds derived from thymine.The design and synthesis of 9-phenylcyclohepta[d]pyrimidine-2,4-dione derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase.Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZT-5'-triphosphate.Nucleoside analogues exerting antiviral activity through a non-nucleoside mechanism.Towards a MIP-based alignment and docking in computer-aided drug design.What can be Expected from Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) in the Treatment of Human Immunodeficiency Virus Type 1 (HIV-1) Infections?Different properties of wild type and drug-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase in vitro.
P2860
Q27755387-5DF4AA95-3DFC-4A27-A785-2A47DEBCFD72Q28343355-49040A86-7212-4AD9-8AAB-4F70D26F19DFQ28343602-F9CDCB74-9B33-44BD-9BF3-A56ECD8DC6C4Q28346130-ABDB32D2-9845-4E28-831B-EDFE49504516Q28362567-BC835E8C-7F2B-41FC-B3BA-7CEF0304D9A2Q28376476-B89A0C8A-9717-4439-9381-BA09140B0DCDQ28376481-B7A19030-B64C-4CF1-8079-FF26C2DCA52AQ28378595-FE18A0FF-286F-48C0-9F89-EA2777317B27Q28378831-5F9881DB-5857-4597-BC1D-4BDA27A56FB9Q28378834-12A948FA-C94B-48B3-AFB4-BFBFE115D846Q28379091-F95FEC27-4CC0-40AA-B226-73B4EE164048Q33303221-48B2CCE6-3019-42C9-BDC3-F070F4C50D00Q33978490-58475FF6-25B0-4CE9-968D-A64F362560EDQ34145448-9408472C-A6DC-4478-BD99-858E46D2A376Q35366050-C92F14CA-28E4-4D71-A7B5-D32D966D0E84Q35375912-B3CE70D6-2C69-4470-BE8B-05CFDADCEA14Q35751916-D45EB0DF-0180-4402-81B0-F7D59AD3D8BCQ35842270-FA135688-8021-4A16-ADE9-14610C7D0172Q37148421-4D6D2DD9-A566-414B-9B46-69579B8F3FE7Q38366289-E88618E1-D98D-4FC2-8942-44F5454370AAQ39819976-37215042-4B9F-481A-BAB1-910CD4ADEB5FQ40042904-0178FCEE-1021-442B-91F7-0DEC8D18FB74Q40055204-3E75A189-78B7-4E56-84C7-E241B33D830EQ40060575-69051C7A-BC76-4BE3-8732-1281F94D424AQ40637184-A72C6A52-C522-4E10-BE79-FAC258E05184Q40794960-CD608807-1B68-40B8-83D8-35F99B6CE841Q40983898-98533774-8DC9-4CDE-9B6D-A56A91C22C3AQ42546011-555F15D8-48D0-4BD7-AD6A-C1D9A8B3E977Q42549470-22DA2E3E-377C-480F-A2B9-749FE9EC3808Q42744297-CBCF8FCF-2B71-4DE5-9C02-782682FD28F4Q43503280-09706E0B-0EE2-44DC-88CB-B563FD656FDEQ43510541-5F2A2840-579A-4C11-937A-197381D4420EQ44375762-7558FE61-1B3E-425A-BB32-0AFDC519BD30Q44548859-0E8681A3-D6D2-451F-888B-2BF865C3770BQ44813648-42BF35AE-EC86-42AE-A4F3-CD6EF8957099Q44960725-EFEBF716-E1F4-4C79-9BA9-332DA700FD12Q45748524-A1C4AA94-ED63-469F-80E2-4DEBB9C4CE64Q45768310-D85C0C51-F42E-417E-A95F-26C8908B13F3
P2860
Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro
description
1994 nî lūn-bûn
@nan
1994 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@ast
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@en
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@nl
type
label
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@ast
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@en
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@nl
prefLabel
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@ast
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@en
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@nl
P2093
P2860
P356
P1476
Preclinical evaluation of MKC- ...... ficiency virus type 1 in vitro
@en
P2093
H Takashima
R T Walker
T Miyasaka
P2860
P304
P356
10.1128/AAC.38.4.688
P407
P577
1994-04-01T00:00:00Z